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Preclinical outcomes of 
Intratumoral Modulation  
Therapy for glioblastoma
Andrea R. Di Sebastiano1, Andrew Deweyert3, Simon Benoit1, Erin Iredale2, Hu Xu1,  
Cleusa De Oliveira3, Eugene Wong2, Susanne Schmid3 & Matthew O. Hebb1,3
Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. 
Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate 
vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical 
outcomes of a novel electrotherapeutic strategy called Intratumoral Modulation Therapy (IMT) that 
uses an implanted stimulation system to deliver sustained, titratable, low intensity electric fields 
directly across GBM-affected brain regions. This pilot technology was applied to in vitro and animal 
models demonstrating significant and marked reduction in tumor cell viability and a cumulative 
impact of concurrent IMT and chemotherapy in GBM. No off target neurological effects were observed 
in treated subjects. Computational modeling predicted IMT field optimization as a means to further 
bolster treatment efficacy. This sentinel study provides new support for defining the potential of IMT 
strategies as part of a more effective multimodality treatment platform for GBM.
Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults, affecting ~1 in 33,333 
people annually and ending the life of an untreated patient within 3 months after diagnosis1. The current stand-
ard of care is surgical resection, when possible, along with radiation and temozolomide (TMZ) chemotherapy. 
Despite maximum available treatment, the cancer inevitably recurs and yields a median survival of only 14 
months1. There is now mounting evidence that electrotherapy may offer new promise as an effective treatment 
modality much needed for GBM patients2. The rationale for this strategy is based on an innate sensitivity of 
GBM cells to non-ablative electric current or fields that are innocuous to normal neural tissues, thus creating 
a putative safety margin for therapeutic development3,4. Such low intensity electrotherapy likely works through 
multiple mechanisms that relate, in part, to disruption of polarized cellular elements necessary for cytokinesis as 
well as changes in membrane permeability and channel homeostasis5,6. There is presently a single electrotherapy 
approved for GBM in the United States. This system includes a portable electric field generator to deliver low 
intensity (1–3 V/Cm), intermediate frequency (200 kHz) alternating electric fields, called tumor treating fields 
(TTFs), to supratentorial brain regions. TTFs are administered through arrays of insulated electrodes adhered to 
the patient’s scalp7. Continuous, long-term application is recommended and the transducer arrays are replaced 
every few days. The clinical impact of TTFs in GBM has been evaluated in two randomized, multi-centre trials8,9. 
The studies had methodological constraints but produced results supporting a significant clinical benefit in both 
recurrent and newly diagnosed disease. Potential drawbacks of TTF therapy include the need for a shaved head, 
frequent electrode changes, scalp complications from chronic electrode wear, stigmata of an external treatment 
device, inability to target infratentorial or spinal disease and high treatment-related costs10,11.
The most common (>90%) pattern of GBM progression occurs as aggressive, continuous extension from the 
site of the original lesion12–15. This important recognition has led to decades of research attempting to develop 
effective locoregional strategies to control growth of inoperable tumors and prevent recurrence following sur-
gical resection16–19. Our group has been pioneering a novel locoregional electrotherapy, called Intratumoral 
Modulation Therapy (IMT), with the premise that an internalized electric field will exploit GBM electrosensi-
tivity to greater advantage and with fewer limitations than an externally applied (e.g., scalp-mounted) source3. 
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Still in the proof-of-concept stage, the clinical vision of IMT uses special purpose, magnetic resonance imaging 
(MRI)-compatible bioelectrodes strategically positioned within, or adjacent, tumor-affected regions of the cen-
tral nervous system (CNS). A key feature of IMT is the ability to reach any aspect of the CNS to provide focused, 
titratable therapy directly within areas of disease. Bioelectrodes could be designed for personalized and com-
prehensive treatment coverage of GBM resection beds or non-operated lesions within eloquent or deep-seated 
CNS regions. The proximity of the IMT field source to GBM pathology will permit a broad, versatile spectrum of 
stimulation parameters custom optimized to tumor location and treatment response. Such a concealed, indwell-
ing system is expected to support patient quality of life while providing sustained, low maintenance therapy that 
potently complements radiation and ongoing chemotherapeutic options.
We recently described an in vitro IMT approach using monophasic, low amplitude (4 V), low frequency 
(130 Hz) square wave pulses that induced apoptosis in patient GBM cells without notable impact on primary neu-
rons3. Adjuvant IMT significantly increased GBM cell death when combined with TMZ or oncogene-targeting 
therapies3. These early results confirmed GBM sensitivity to directly applied, non-ablative electrical pulses but the 
low frequency parameters posed risk of neuronal entrainment and off-target neurological effects if applied within 
eloquent CNS areas20. The objective of the present study was to evaluate a novel profile of IMT parameters using 
intermediate frequency (200 kHz) stimulation with low risk of neuronal entrainment and a sinusoidal waveform 
to deliver continuous, alternating polarity, low intensity (±2 V) electric fields. These new parameters were first 
validated using our established in vitro methods then translated to test IMT for the first time in a customized in 
vivo GBM model.
Results
Intermediate frequency IMT selectively kills GBM cells and provides cumulative anti-neoplastic 
effects when administered with TMZ chemotherapy. The MTT assay generated spectrophotometric 
values that reflected cell viability. Results of each treatment condition were normalized to those of the sham 
group. GBM cells from 3 patient tumors were independently treated and the data pooled for analysis. The indi-
vidual MTT values are provided in Table 1. TMZ produced a modest but significant reduction in patient GBM 
cell viability to 82.6 ± 3.0% (P = 0.001), whereas IMT resulted in a greater drop to 65.1 ± 4.0% (P < 0.001) of 
sham values. Co-administration of TMZ with IMT resulted in a dramatic cumulative loss of GBM cell viability 
to 45.8 ± 4.0% (P < 0.001) of sham values (Fig. 1). The difference in GBM cell viability between TMZ and IMT 
(P < 0.001), and between TMZ (P < 0.001) or IMT (P < 0.001) and the combined TMZ + IMT treatments were 
all highly significant. The F98 GBM cells were similarly vulnerable to IMT, with a reduction to 54.9 ± 6.3% (N = 3; 
P = 0.008) of sham values. In contrast, primary neuronal cultures did not exhibit obvious changes in morphol-
ogy nor were the MTT measures notably affected by IMT, with a mean group viability of 105.5 ± 5.3% (N = 4; 
P = 0.091) of sham values (Fig. 1).
Flow cytometry with Annexin V and PI labeling permitted quantification of live, apoptotic and dead GBM 
cell fractions. Primary neurons were not able to withstand the flow cytometry methods. The assay was conducted 
on 15–30,000 GBM cells for each treatment condition using biological replicates from 3 patients. The values for 
apoptotic and dead cells were combined into a single category. The flow cytometry revealed 15.1 ± 12.2% apop-
totic/dead GBM cells in the sham group compared with a progressive increase in this fraction following treatment 
with TMZ (28.2 ± 7.1%; P = 0.488), IMT (38.8 ± 6.0%; P = 0.032) and the combination TMZ + IMT (73.7 ± 2.1%; 
P < 0.001; Fig. 2; Table 2).
IMT significantly attenuates GBM growth in vivo. The syngeneic rodent F98 GBM model was custom-
ized to evaluate IMT efficacy against GBM in the living brain (Fig. 3A–C). The treatment period spanned post-
operative days 4–11 during which no neurological, behavioral or pain symptoms related to the stimulation were 
observed. Of the original 25-animal cohort, 15 animals were included in the final analysis. The excluded animals 
were: 4 with evidence of overt infection extending into the brain, 1 with insufficient tumor take, 3 with incomplete 
histological preparations and 2 that expired from undetermined causes. The first death occurred on postoperative 
day 3, prior to initiating IMT. The second death occurred 3 days after IMT initiation. The brain of this animal was 
examined histologically and no evidence of treatment-related complication (e.g., electrolysis, hematoma) was 
identified. In addition to the 25-animal cohort, control animals with unilateral tumor-only implants (N = 4) eval-
uated on postoperative day 4 (i.e., the time point of IMT initiation) revealed the expected GBM growth consistent 
across the group (Fig. 3D). Animals that received IMT and sham treatments without previous GBM implants 
(N = 3) revealed no obvious stimulation-related injury to normal brain parenchyma (Fig. 3E).
GBM # Temozolomide IMT Temozolomide + IMT
1 0.79 0.68 0.49
2 0.85 0.67 0.47
3 0.84 0.59 0.41
Table 1. Spectrophotometric viability (MTT) analysis in patient GBM cells. Shown are the MTT values, 
normalized to the respective sham control, for GBM cells obtained from 3 patients. Cells were exposed to the 
indicated conditions for 3 days preceding analysis. IMT was statistically superior to temozolomide in reducing 
GBM cell viability and the combination of temozolomide and IMT produced dramatic, highly significant anti-
neoplastic effects. These data are summarized in Fig. 1.
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The bilateral GBM tumors were randomized to sham treatment or IMT, with 8 right- and 7 left-sided tumors 
receiving IMT by the end of the study. GBM tumors that received IMT were typically more rounded and com-
pact compared to the oblong, irregular configuration of sham-treated lesions. GBM volumes were estimated 
through the rostrocaudal extent of the tumor (‘whole tumor’) and also within a core region at the presumed 
centre of the IMT electric field (‘core tumor’). The whole tumor measures revealed smaller IMT-treated, com-
pared to sham-treated, tumors in 11/15 (73%) animals. There was a single, statistically-proven outlier (subject #7) 
in which the discrepancy between IMT- and sham–treated tumors was drastically reversed. The reason for this 
finding was not identified, however hypothesized to be technical in origin, such as a problem with the GBM 
implant or the laterality marker. The change in tumor volume for this animal fell well past 2 standard devia-
tions from the mean (i.e., >95th %-ile of the normal data distribution) and was identified by both the Dixon’s 
(P = 0.028) and Grubb’s (P = 0.016) tests as a significant outlier. The statistical evidence supported its exclusion; 
however the cumulative GBM measures for the entire cohort were calculated both in the presence and absence 
of the outlier subject (Figs. 4 and 5). With the outlier included, there was a non-significant 14.5% reduction in 
IMT-treated whole tumor volume (P = 0.107) that rose to a significant 19.5% reduction (P = 0.047) with the out-
lier excluded (Table 3). The percent change in the IMT tumor volume relative to that of the sham tumor was also 
calculated in each subject and averaged over the cohort. These data aligned with the cumulative tumor measure 
analysis and showed that with inclusion of the outlier, IMT produced a whole tumor reduction of 12.7 +/− 35.8% 
(P = 0.096). With subject #7 excluded, the volume reduction of the IMT-treated GBM increased to a highly sig-
nificant 19.7 +/− 24.3% (P = 0.005).
Figure 1. Impact of intermediate frequency IMT on GBM cells in vitro. Brightfield photomicrographs of 
patient and rodent F98 GBM cells and primary neurons are shown following a 3-day exposure to the indicated 
treatments. The images captured cell fields adjacent to the bioelectrode implanted within the cultures (not 
shown). (A) Patient GBM cells stained with the dark MTT chromogen demonstrate robust viability under 
sham conditions. A moderate reduction in staining, accompanied by pyknosis and decreased cell density 
was observed with (B) TMZ or (C) IMT monotherapy. (D) Concomitant TMZ+IMT resulted in a dramatic 
loss of cell viability compared to that achieved with either treatment alone. (E,F) Susceptibility to the same 
stimulation parameters was also evident in rodent F98 GBM cells as shown by MTT staining. (G,H) In contrast, 
the morphology and density of post-mitotic primary neuronal cultures, as shown here following trypan blue 
exposure, was not notably affected by IMT. (I) The viability of GBM cells from 3 different patient tumors was 
significantly reduced by TMZ or IMT alone. A cumulative GBM cell loss was produced by the combination of 
both treatments, likely reflective of distinct mechanisms of action. Asterisks directly above the data bars indicate 
a significant (P < 0.001) difference from the sham control. The significance (P < 0.001) between indicated data 
pairs is depicted by an asterisk above the horizontal lines. (J) F98 GBM (N = 3; P = 0.008) but not (K) primary 
post-mitotic neuronal (N = 4; P = 0.091) cultures were susceptible to IMT. Asterisks directly above the data bars 
indicate a significant difference from the sham control. All data are presented as mean ± standard deviation.
www.nature.com/scientificreports/
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Core tumor analysis focused on the GBM region nearest the bioelectrode and identified 12/15 (80%) animals 
with smaller IMT-treated, compared to sham-treated, core tumors. Subject #7 was again identified as a statistical 
outlier using the Dixon’s (P = 0.004) and Grubb’s (P = 0.002) tests. Cumulative core GBM burden for the whole 
group was 19.7–23.7% smaller in IMT tumors compared to sham controls, a highly significant response regard-
less of the outlier measure (Table 3). There was also a significant mean individual reduction of 15.8 +/− 32.0% 
(P = 0.038) when assessed with the outlier included. This measure rose to 22.7 +/− 18.3% (P = 0.0002) with the 
outlier excluded.
Computer simulation predicts IMT electric field properties in GBM tumor and brain. These stud-
ies sought to define the extent of in vivo treatment coverage produced within the GBM environment using the 
present IMT hardware and stimulation parameters. IMT electric field modeling was performed in a representa-
tive 7-day rodent GBM to best estimate the tumor size and brain conditions at the mid-way point of the current 
IMT protocol which extended between days 4–11 following GBM cell implantation. The simulation analysis 
demonstrated a tightly constrained electric field centered near the core of the GBM mass with radial extension to 
a modest fraction of the tumor and surrounding edematous brain (Fig. 6). The amplitude of the IMT electric field 
decreased logarithmically with the radial distance from the bioelectrode. Field strengths of 4 V/cm, 3 V/cm, 2 V/
cm and 1 V/cm extended to 0.32 mm, 0.43 mm, 0.63 mm, 1.24 mm, respectively, from the source. It was estimated 
that the fractions of GBM tumor that received an IMT electric field amplitude above these thresholds were 3.0%, 
Figure 2. Flow cytometry measures of IMT response in patient GBM cells. (A) Representative scatterplots 
of annexin and propidium iodide (PI) labeling of apoptotic and dead patient GBM cells, respectively, after a 
3-day exposure to the indicated treatment. IMT produced a greater cytotoxic effect than TMZ but the number 
of apoptotic and dead GBM cells rose dramatically with combined therapy. (B) Quantitative flow cytometry 
revealed a significant difference (P < 0.001) between live and apoptotic/dead fractions within each of the sham, 
TMZ and TMZ+IMT groups, but not in the IMT group (P = 0.053). This corresponded to a significant loss 
of GBM cell viability with IMT, but not TMZ, and a cumulative increase in cytotoxicity with the combination 
of the two treatments. These studies were performed in triplicate using primary GBM cells from 3 different 
patients. Asterisks directly above the data bars indicate a significant difference from the respective sham value 
(e.g., live compared to live). Significance between indicated data pairs is depicted by the asterisk(s) above the 
horizontal lines. Data are presented as mean ± standard deviation with significance indicated at P *< 0.05,  
**< 0.01 and ***< 0.001.
GBM #










1 91.0 8.68 70.3 29.2 59 40.5 23.4 76.1
2 92.5 7.49 79.4 20.6 67.5 32.1 27.04 72.8
3 70.4 29.26 64.8 34.7 55.6 43.7 26.7 72.2
Table 2. Individual flow cytometry measures of IMT response in patient GBM cells. Shown are the percentages 
(%) of live (Annexin−/PI−) versus apoptotic (Annexin+/PI−) or dead (Annexin+/PI+) patient GBM cells 
quantified with flow cytometry. Each condition was evaluated in 3 biological replicates with 15,000–30,000 
patient GBM cells exposed to the indicated treatment for 3 days. The differences in therapeutic impact between 
groups were highly significant and are summarized in Fig. 2.
www.nature.com/scientificreports/
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4.8%, 9.5% and 24.2% respectively. When combining the regions of GBM tumor and associated edematous brain, 
the fractions predicted to receive these field thresholds were 0.5%, 1.0%, 2.4% and 12.1%, respectively (Fig. 7).
Discussion
This preclinical study is, to our knowledge, the first to demonstrate the efficacy of an implantable electrotherapy 
using non-ablative, intermediate frequency stimulation in patient-derived GBM cells and in a cohort of living 
animals with intracerebral GBM. Primary GBM cells, but not neurons, were exquisitely sensitive to low ampli-
tude, sinusoidal pulses at a frequency out of range for neuronal entrainment or thermal injury20,21. IMT-mediated 
cytotoxicity was largely apoptotic and enhanced GBM cell death when co-administered with TMZ chemotherapy. 
This in vitro proof-of-concept was translated to an animal model in which a 1-week course of continuous IMT 
monotherapy produced a significant reduction of mean GBM volume in the living brain. These highly promis-
ing data likely do not reflect the full potential of IMT. There are technical and biological aspects of the present 
in vivo model which may have led to an underestimation of therapeutic efficacy. For example, the rudimentary, 
single-contact bioelectrode and applied stimulation parameters were predicted to generate an IMT electric field 
≥1 V/cm (i.e., the lower threshold recommended for the external TTF device) throughout only ~24% of the esti-
mated volume of a 7-day tumor11. The compact IMT field dimensions (i.e., ~1.24 mm radius for a ≥1 V/cm field) 
would poorly accommodate a suboptimally positioned bioelectrode, particularly if located near or beyond the 
GBM boundary, which may explain the inter-animal variability in treatment response. The measured therapeutic 
impact, while significant, was likely less than what may be achieved using hardware and stimulation parameters 
that provide comprehensive coverage of the tumor-affected region. The large GBM burden in the F98 model also 
created a greater treatment challenge than would be expected with small volume or recurrent/residual tumors. In 
our hands, a deposit of 40,000 F98 cells produced robust growth, expanding into moderate-sized lesions as early 
as day 4 and massive GBM tumors with cerebral edema and central necrosis by day 11 post-implantation. Others 
have reported a mean survival between 18–25 days in rats harboring these GBM tumors22,23. Anecdotally, the rate 
of growth may be proportionally greater than typical for GBM in humans, creating a highly formidable model in 
which to evaluate a putative new therapeutic device.
The development of an indwelling electrotherapy for GBM is predicated on a global experience using deep 
brain stimulation (DBS) devices engineered to treat non-oncological conditions, such as movement, pain, psy-
chiatric and seizure disorders24,25. DBS entails stereotactic placement of in-line, multi-contact leads into target 
brain regions, controlled by a remote-accessed, implantable pulse generator. This technology typically delivers 
continuous, monophasic, square wave pulses at low amplitude (e.g., 1–5 V) and frequency (e.g., 90–185 Hz) to 
Figure 3. In vivo model to evaluate IMT in GBM. (A) Schematic and (B) photographic depiction of the 
in vivo IMT model. The animals could roam freely throughout the home cage. Bilateral GBM tumors were 
randomized so that one would receive sham treatment (i.e., hardware but no stimulation) and the other IMT 
between postoperative days 4–11. This provided an internal control tumor for every subject. (C) The IMT 
construct consisted of a lead with a single 1-mm stimulating bioelectrode, a cannula to deliver the GBM cells 
and a reference bioelectrode. The stimulating bioelectrode was located at the core of the GBM tumors and the 
reference bioelectrode positioned extracranially under the scalp. (D) Representative thionine-stained section  
of a control brain demonstrating a 4-day GBM, reflecting the tumor size when IMT was initiated (arrow).  
(E) Representative thionine-stained section through another control brain to show the effects of IMT on normal 
parenchyma. There was no tumor in this subject however bilateral IMT constructs were placed for delivery 
of 1 week of sham (left) or IMT (right). Symmetric hardware defects were evident (asterisks) without overt 
parenchymal injury from the stimulation.
www.nature.com/scientificreports/
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disrupt and entrain pathological firing patterns in a reversible, non-injurious manner26. DBS and IMT are starkly 
different in indication, operational parameters and hardware design. The electrical output of prospective IMT 
systems will be defined by non-ablative pulses coupled to customized and distinct profiles of waveform, polarity, 
and frequency parameters titrated to individual tumor response and location. This study utilized a low amplitude 
(+/−2 V), intermediate frequency (200 kHz), sinusoidal waveform with reversing polarity intended to maximally 
disrupt electrical homeostasis in GBM cells. The pulse frequency was 1000-fold higher than typical for DBS and 
well beyond the range of neuronal entrainment so not to incite adverse neurological effects when stimulating 
tumor-infiltrated CNS regions. This amplitude and frequency are also below the threshold for producing ther-
mal injury and have been shown to selectively target GBM cells with relative safety in preclinical studies and 
human TTF therapy3,4,7,21. The irregular and variable anatomy of GBM disease also mandates unique IMT hard-
ware design. Rather than a single, in-line row of contacts typical of DBS systems, comprehensive tumor coverage 
requires bioelectrodes with versatile, multi-dimensional configurations driven by a field generator capable of 
producing a unique spectrum of IMT parameters. DBS has traditionally used a voltage-driven treatment plat-
form, however newer devices are available that utilize constant current parameters with or without directional 
control27,28. Tight regulation of current flow within disease-affected brain regions may provide greater thera-
peutic impact when the goal is to re-program pathological firing patterns in non-oncological disease; however, 
it remains unknown whether the same logic applies to electrotherapies designed for CNS cancer. Conductive 
(uninsulated) bioelectrodes may be powered by a voltage-driven system with the resultant current flow gated 
by local tissue resistivity. The heterogeneous architecture of the brain and GBM tumors would result in constant 
voltage with variable and dynamic current flow. In contrast, the same bioelectrodes powered by a constant cur-
rent platform could provide a defined rate of flow maintained by feedback modulation that adjusts the voltage 
to accommodate varying resistivity. A third option for IMT delivery is to establish an intratumoral electric field 
without current flowing between the bioelectrodes and the tissues using non-conductive (insulated) bioelec-
trodes within the GBM-affected region. In the present work, IMT was voltage-driven with a peak-to-peak pulse 
amplitude of 4 volts (±2 V) which did not elicit overt behavioral changes, seizures or focal neurological deficits, 
nor histological evidence of electrolysis in the brain or tumor. As a pilot investigation, a small fraction (2/15) of 
the cohort received insulated bioelectrodes with other IMT parameters remaining constant. There was a positive 
treatment response in these animals measured by both whole and core tumor analysis, indicating that an applied 
intratumoral electric field may be sufficient to attenuate tumor growth. Further studies are needed to define the 
properties of conductive versus non-conductive implanted bioelectrodes in GBM disease.
Figure 4. IMT attenuates locoregional GBM growth in vivo. (A) Representative, thionine-stained brain 
sections from 6 animals with GBM treated throughout this study. The 7-day course of IMT was randomized 
to the right or left GBM (treatment sides have been aligned in this figure for comparative purposes), with the 
contralateral tumor used as a sham control. The subject identifier is shown to the upper left of each section. 
GBM volumes were estimated by cumulative cross-sectional tumor areas quantified using ImageJ software, as 
demonstrated by the yellow tracing in subject 9. (B) The difference in estimated whole (i) and core (ii) GBM 
volume following IMT, relative to the internal sham control, is provided for every animal. Negative values 
are consistent with treatment response. The whole tumor measures incorporate serial sections through the 
rostrocaudal extent of the GBM whereas the core tumor measures were limited to the region surrounding the 
bioelectrode. There was one outlier (#7, shown in gray) with a reversal of expected effects, presumed technical 
in origin. (C) Distribution plots showing volume differences in the IMT-treated i) whole and ii) core tumor 
over 10% intervals. For example, a data bar on the −50% tick mark depicts the number of animals that had a 
50–60% tumor reduction. The solid black-to-white lines indicate the cohort means when the data included the 
outlier shown in gray. The dashed lines indicate the standard deviation of this mean. Note that the outlier is well 
beyond 2 standard deviations of the mean. The red lines depict the cohort means with the outlier excluded.
www.nature.com/scientificreports/
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This study demonstrated the in vitro efficacy of intermediate frequency IMT in patient GBM cells and showed 
that a rudimentary, pilot IMT device could significantly reduce GBM volume across a 15-animal cohort. This is 
the first demonstration that GBM tumors may be therapeutically impacted using an implantable system to chron-
ically deliver low intensity, non-ablative electric fields. The current data provide strong justification to develop 
IMT hardware and application settings that provide more comprehensive tumor coverage and, hopefully, 
enhanced therapeutic benefit. Successful advances in IMT technology could lead to a novel treatment modality 
desperately needed for GBM and other high fatality CNS cancers.
Materials and Methods
GBM cell cultures. These protocols were approved by the Human Research Ethics Board and the Animal 
Care Committee at Western University and carried out in accordance with the Tri-Council Policy for research 
involving human subjects and the Canadian Council on Animal Care. Informed consent was obtained from all 
patients or their legal guardians prior to using their GBM tissue in this study. Human GBM cells were isolated 
from operative tumor specimens obtained from 3 patients (39 y male, 44 y female, 65 y female). Specimens were 
not genetically screened for study purposes. The tumor samples were collected into phosphate-buffered saline 
(PBS) with 0.5% fetal bovine serum (FBS; Life Technologies) at the time of surgery. The tissue was digested and 
filtered then suspended in Dulbecco’s modified Eagle’s medium (DMEM; Wisent Bioproducts) supplemented 
with 10% FBS, 1% non-essential amino acids and 1% penicillin/streptomycin (Life Technologies). Homogenates 
were plated on a 35 mm dish for 30 minutes to allow for separation of blood cells. The upper cell suspension was 
then transferred to two wells of a 24-well plate, freshly pre-coated with 10 µg/ml poly-L-lysine (Trevigen Inc) and 
incubated at 37 °C with 5% CO2. Cultures were passaged at approximately 80% confluence and split 1:2 using 
Figure 5. Paired in vivo GBM responses to sham and IMT conditions. Raw tumor measures calculated from 
the (A) whole tumor and (B) core tumor are shown after sham treatment (black) or IMT (white). The statistical 
outlier shown in Fig. 4 has been left in this dataset for completion (subject #7; labeled O). The IMT-treated 
GBM was smaller than the sham-treated tumor in 11 of 15 (73%) and 12 of 15 (80%) subjects using whole and 
core tumor measures, respectively.
Cumulative whole 
tumor volume 
(pixels × 106) Whole tumor reduction 
with IMT (%) P-value
Cumulative core 
tumor volume 
(pixels × 106) Core tumor reduction 
with IMT (%) P-valueSham IMT Sham IMT
Outlier included 366.3 313.4 14.5 0.107 176.6 141.9 19.7 0.015
Outlier excluded 356.2 286.9 19.5 0.047 169.7 129.5 23.7 0.002
Table 3. Cumulative in vivo tumor burden in sham and IMT-treated GBM within the 15-animal cohort.
www.nature.com/scientificreports/
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0.25% trypsin with 0.53 mM ethylenediaminetetraacetic acid (EDTA; Wisent). The medium was changed twice 
per week. All assays were conducted using GBM cells from cultures at passages 4 through 12.
The F98 GBM cell line (CRL2397™; ATCC) was originally created following a single N-ethyl-N-nitrosourea 
injection to a pregnant Fischer rat to produce offspring with malignant glioma tumors that were then maintained 
in culture22,23. The low immunogenicity of F98 cells in syngeneic Fischer rats offers advantages over xenogeneic 
and allogeneic models that require immunosuppression or may exhibit spontaneous tumor regression. F98 GBM 
tumors are highly proliferative, invasive and recalcitrant to conventional therapies, closely mimicking the human 
disease. F98 cells were cultured in 100 mm dishes in DMEM supplemented with 10% FBS, 1% non-essential 
amino acids and 1% penicillin/streptomycin (Life Technologies) in a humidified incubator at 37 °C with 5% CO2. 
The medium was changed twice per week and cultures passaged at ~80% confluence and split 1:2 using 0.25% 
trypsin with 0.53 mM EDTA (Wisent).
Primary neuronal cultures. IMT was evaluated in post-mitotic primary neurons isolated from embryonic 
rat brains (N = 3). Cerebral cortices from E18 Wistar embryo were dissected into a 14 ml conical tube containing 
Figure 6. Image-based simulation of IMT electric fields. A 9.4T MRI system was used to generate true fast 
imaging with steady state precession (TrueFISP) images of a 7-day GBM tumor in the rodent brain. Coronal 
(A,B) and sagittal (D,E) images are shown. (A,D) Brainsuite software (v.16a1) was used to segment the tumor 
(yellow trace) and edema (turquoise trace). The segmented volumes were imported to COMSOL Multiphysics 
(v.5.2a), where the intratumoral bioelectrode and cannula geometries were simulated. (B,E) The conductance 
and dielectric values of the hardware (bioelectrode, black arrow; cannula, white arrow) and neural elements 
were used with the boundary condition of constant voltage amplitude of 2.0 V at 200 kHz for the bioelectrode 
and the reference electrode applied outside the skull. The resulting map of the electric field magnitude was 
exported and combined with the TrueFISP MR images for visualization in 3D Slicer (v.4.4.0). The electric field 
data within the tumor was analyzed using MATLAB R2015b to estimate the fraction of tumor receiving specific 
field amplitudes (see Fig. 7). Three-dimensional rendering of the rodent brain shown in (C) coronal and (F) 
oblique sagittal views depict the relationship between the 1) intratumoral bioelectrode, 2) cannula, 3) GBM 
mass and 4) region of tumor-associated cerebral edema. S, superior; I, inferior; M, medial; L, lateral; A, anterior; 
P, posterior. The scale bar in B corresponds to panels A and B; that in E to panels D and E; both depict 5 mm.
Figure 7. Predicted relations between IMT electric field amplitude, radial field dimensions and extent of GBM 
region coverage in the present in vivo treatment model.
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1.8 ml of Hank’s balanced salt solution (HBSS; Wisent) and centrifuged at 4000 × g for 1 min at room temperature. 
HBSS was aspirated and 1.8 ml of solution A containing 5 ml HBSS, 6 μl MgSO4 (1 M) and 2 ml trypsin (Sigma 
Aldrich) were added. The tube was mixed well and placed in an automated rotator at 37 °C for 25 minutes. After 
rotation, 3.6 ml of solution B containing 7 ml HBSS, 8 μl MgSO4 (1 M), 175 μl DNase1 (10 mg/ml) and 112 μl 
trypsin inhibitor (100 μg/ml; Roche Life Sciences) were added and mixed for 2 minutes, centrifuged at 4000 × g 
for 5 min at room temperature, and then the HBSS was aspirated. Finally, 6 ml of solution C containing 20 ml of 
HBSS, 48 μl MgSO4 (1 M), 1.3 ml DNase1 (10 mg/ml), and 1 ml trypsin inhibitor (100 μg/ml) were added to the 
resulting cell pellet (Roche). These cells were transferred to a 50 ml falcon tube and another 6 ml of solution C 
was added. The cells were titrated, centrifuged at 4000 × g for 5 minutes and the supernatant aspirated. The cell 
pellet was re-suspended in 36 ml of media containing 96% neural basal media (Wisent), 2% B27 supplement, 0.8% 
N2 Supplement, 0.5% penicillin/streptomycin, 0.25% Glutamax (Life Technologies), and 0.1% Amphotericin 
B solution (Sigma Aldrich). Cells were counted with a hemocytometer, plated in 35 mm wells coated with 7% 
poly-L-Ornithine (Sigma Aldrich) at density of 0.5 × 106 cells/well and kept in a humidified incubator at 37 °C 
with 5% CO2. On the third day of culture, the media was changed and wells were fitted with the IMT apparatus 
for delivery of 72 h of sham or IMT conditions.
In vitro IMT model. The impact of IMT alone and combined with TMZ was independently evaluated in trip-
licate using primary human GBM cells, rodent F98 GBM cells and post-mitotic rodent primary neurons. GBM 
cells and primary neurons (1–5 × 105 cells) were cultured in 35 mm wells in standard 6-well plates. GBM cells 
were grown to ~70% confluence before treatment. The IMT model was created by fitting each well with a clinical 
grade, platinum-based strip bioelectrode (AD-Tech) around the periphery and a single contact platinum-iridium 
bioelectrode (Medtronic Ltd.) at the center of the well and cell culture3. A waveform generator (Rigol DG1022; 
Electro-Meters Ltd.) was used to deliver biphasic sinusoidal pulses with low amplitude (+ /−2 V; peak-to-peak 
4 V) and intermediate frequency (200 kHz) for a period of 72 hours. Control wells (i.e. sham-treated) were fitted 
with electrodes but no current was delivered. GBM cells treated with chemotherapy were plated with DMEM con-
taining TMZ (50 μM; Sigma Aldrich) and received 72 hours of concomitant IMT or sham conditions. This TMZ 
concentration reflects clinically relevant levels corresponding to the in vivo plasma concentration of 150 mg/m2 
in the adjuvant phase of GBM treatment29.
Cell viability assays. Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
(MTT) spectral analysis (Sigma Aldrich). This spectrophotometric assay measures the reduction of yellow MTT by 
mitochondrial succinate dehydrogenase to an insoluble, dark purple Formosan product. Immediately following the 
GBM cell treatments described above, MTT (80 µl at 5 mg/ml) was added to the 35 mm wells and incubated for 3 hours 
at 37 °C in a humidified 5% CO2 atmosphere. The cells were then lysed to release the purple Formosan product by 
the addition of 600 µl dimethyl sulfoxide for 15 minutes at room temperature. Absorbance was measured using an 
enzyme-linked immunosorbent assay plate reader (Fisher Scientific). Cell viability was estimated using optical density 
values at 570 nm with references at 655 nm detected in each well.
Trypan blue exclusion was used as a confirmatory, qualitative measure of cell viability. Briefly, 0.1 ml of a 0.4% 
trypan blue solution (Lonza) was added for every 1 ml culture media and the cells incubated for 2 minutes at room 
temperature. Brightfield images of cells stained with MTT and trypan blue were obtained using a Motic AE31 
inverted microscope fitted with an Infinity 1–3 scientific complementary metal-oxide semiconductor camera 
(Lumenera Corp).
An Annexin V Apoptosis Detection Kit with propidium iodide (PI; BioLegend) was used to quantify live, 
apoptotic and dead GBM cell fractions, as per the manufacturer’s instructions. Cell fractions were analyzed using 
a Becton Dickinson LSR II SORP flow cytometer running FACSDiva software (BD Biosciences). Cells were first 
gated on forward scatter (FSC−) versus side scatter (SSC−) characteristics before excluding doublets using con-
secutive gating FSC-Area versus FSC-Width and SSC-Area versus SSC-Width plots. The populations of annexin 
V+/PI−, annexin V+/PI+, annexin V−/PI+ and annexin V−/PI− were then calculated with quadrant gates. 
Approximately 15,000–30,000 single GBM cells were acquired per each of three patient samples at a maximum 
event rate of 5,000 events per second. Data were analyzed using FlowJo v 9.6.3 (TreeStar, Inc).
In vivo GBM model and IMT. Bilateral orthotopic GBM tumors were established by implanting F98 cells 
into the brain of syngeneic adult female Fischer rats (Charles River)22,23. A cohort size of 25 was chosen to ade-
quately temper inter-animal variability and account for unexpected problems or deaths. Subjects were maintained 
under isoflurane anesthesia for stereotactic implantation of chronic cannula-bioelectrode constructs (Plastics 
One) into bilateral striata (coordinates from bregma: anteroposterior 1 mm, lateral +/−3 mm, dorsoventral −6 
mm). The constructs consisted of a 5 mm long steel cannula with 1 mm luminal diameter, running parallel to a 
6-mm-long, rigid lead with a 1 mm long, 0.25 mm diameter bioelectrode contact at the distal tip. The reference 
bioelectrode was connected by a flexible 1 cm long insulated wire and positioned extracranially in the temporal or 
nuchal soft tissues. These three components were secured at a common, accessible pedestal cemented to the skull. 
A key advantage of this cannula-bioelectrode construct was the ability to implant GBM cells that form a large 
tumor mass centered around the IMT bioelectrode within the brain. In two animals (#10, 11), the bioelectrode 
contact was insulated with a thin layer of Entellan® (Sigma Aldrich) prior to implantation. This pilot modification 
was intended to assess the anti-GBM effect of an intratumoral electric field without current flowing between the 
bioelectrodes and tissue.
F98 GBM cells (4 × 104 in 2 µl DMEM) were delivered bilaterally through the implanted cannulae, after which 
the pedestal was covered with a protective cap. Two operators were present for quality assurance in all surgeries. 
On postoperative day 4, IMT was randomized to the right or left tumor and the respective bioelectrode was con-
nected to a waveform generator (Rigol DG1022; Electro-Meters Ltd) via an extension cable and a commutator 
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that permitted the animal to move freely throughout the home cage. The contralateral tumor served as an internal 
sham control (i.e., identical tumor and hardware implants but without stimulation). Continuous IMT mono-
therapy was delivered between postoperative days 4–11 using the in vitro parameters (i.e., sinusoidal waveform, 
+/−2V, 200 kHz). Three control subjects received bilateral hardware without GBM cell delivery to assess poten-
tial adverse effects of IMT on normal brain structure. Five subjects had unilateral implantation of GBM cells, as 
described above, using a Hamilton syringe and without IMT hardware. Four of these subjects were used to assess 
GBM size after 4 days of growth (i.e., the size at the onset of IMT). One animal underwent MRI on postoperative 
day 7 as part of the simulation studies, described below. All animals were given free access to food and water, 
perioperative antibiotics and analgesics, and monitored daily for medical or neurological complications. On post-
operative day 11, animals were deeply anesthetized with sodium pentobarbital and transcardially perfused with 
4% paraformaldehyde. The brains were extracted, cryoprotected and frozen. Brains were cut into 16–35 µm thick 
sections through the rostrocaudal extent of the tumors, mounted onto microscope slides and stained with thio-
nine. Processed sections were digitally imaged with a Nikon Eclipse Ni-E microscope.
GBM tumor analysis. Digitized brain images were imported into ImageJ v.2.0.0 software for tumor meas-
urement by a blinded observer. The wand tracing tool was used to select the GBM tissue from surrounding brain 
with identical tolerance detection settings for the IMT- and sham-treated tumors. Tolerance detection ranged 
from 10–40 pixels in 8-connected mode and was adjusted accordingly between serial sections for variations in 
staining intensity. Cross-sectional areas in serial sections were quantified in pixels and summed to provide relative 
estimates of tumor volume. The whole tumor was measured using serial sections through the rostrocaudal extent 
of the GBM. A more focused measure of the tumor ‘core’ was calculated to assess the impact of IMT in the region 
of highest GBM burden (i.e., at the implantation site) and anticipated center of the IMT electric field. This core 
region was objectively defined within 4 brain sections containing the largest cross-sectional area of both sham- 
and IMT-treated tumors in addition to the two immediately flanking sections.
IMT electric field simulation. The IMT electric field created by the treatment parameters used in this study 
was simulated based on 9.4 T MRI data from a representative control animal with a unilateral 7-day GBM, as 
described above. Imaging at this time point depicts the tumor size midway through the treatment period (i.e., day 
4–11). MRI data was imported to Brainsuite v.16a1 for segmentation of the GBM tumor mass, associate cerebral 
edema, whole brain and skull. Segmented volumes were then imported to Multiphysics v.5.2a (COMSOL Inc.) 
where the intratumoral bioelectrode, reference bioelectrode and cannula geometry was simulated according to 
the in vivo IMT paradigm. The bioelectrode was modeled with stainless steel insulated with a 0.025 mm thick 
layer of polyimide except for the distal tip where a 1 mm contact was exposed. The conductance and dielec-
tric properties of the segmented brain tissues, skull and bioelectrode apparatus were then specified within the 
COMSOL Electric Currents user interface which was employed to compute the electric field30,31. A constant 
voltage of 2.0 V at 200 kHz was applied across the intratumoral and reference bioelectrodes within this computer 
model. The resulting map of the electric field amplitude was exported and merged with the MR images for visu-
alization in 3D Slicer v.4.4.0. The dimensions and amplitude of the electric field within the tumor and brain were 
analyzed using MATLAB R2015b (MathWorks Inc).
Magnetic resonance imaging. MRI studies were performed at The Centre for Functional and Metabolic 
Mapping, Robarts Research Institute, Western University. An Agilent small animal 9.4 T MRI unit was used 
to obtain true fast imaging with steady state precession (TrueFISP; TR = 7 ms, TE = 3.5 ms, flip angle = 30 
degrees, number of frequencies = 4, number of averages = 4, total acquisition time = 42 minutes, field of 
view = 28 mm × 28 mm × 28 mm, acquisition matrix = 140 × 140 × 140).
Statistical analysis. A t-test or Wilcoxon signed-rank test was used to compare single and paired in vitro 
data sets that followed or deviated from a normal distribution, respectively. Multiple pairwise comparisons were 
performed using one-way analysis of variance (ANOVA) followed by Tukey post-hoc analysis. In vivo tumor 
measures were evaluated using the Dixon’s and Grubb’s tests for outliers. The in vivo IMT response was assessed 
by calculating the percent change in tumor volume for each subject and using a single sample t-test to compare 
the cohort values to a hypothetical mean change of zero percent. A complementary analysis did not assume 
uniform untreated rates of growth amongst tumors and compared the cumulative GBM burden following sham 
and IMT treatment within the entire cohort using a paired sample t-test. One-tailed analyses were used for statis-
tical comparisons based on the known in vitro efficacy of IMT against GBM3. Statistical software used included 
SigmaStat (Systat Software Inc) and SPSS v 14.0 (IBM). Data are presented as mean ± standard deviation with 
significance assumed at p < 0.05.
Data availability. All data analysed during this study are included in this published article.
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